Proniras Corporation is a biotechnology company focused on developing tezampanel as a potential treatment for opioid withdrawal and related disorders of addiction. Although effective treatments exist for opioid addiction, painful and difficult withdrawal is one of the reasons treatment fails and relapse occurs. By alleviating symptoms associated with opioid withdrawal, Proniras hopes to help patients complete their discontinuation of opioids and facilitate successful treatment. The development of tezampanel for opioid withdrawal is supported by federal funding from the National Institute on Drug Abuse (NIDA), under Grant No. 1UG3DA050923-01.